Please assess the completion status of the following clinical trial:

Trial Title: THISTLE - The HIV-HCV Silibinin Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Age greater or equal 18 years~* HIV-HCV co-infection~* HCV Genotype 1 infection~* At least one liver biopsy since diagnosis of HCV-infection~* Fibrosis score METAVIR = 2 documented by biopsy OR a stiffness greater or equal 7.0 kPa documented by fibroscan during the previous 12 months.~* Documented previous null-response or partial-response to SOC~Exclusion criteria:~* Contraindications to the study drug under study, e.g. known hypersensitivity or allergy to any ingredient of the study drug~* Patients in need of ART with HIV virological failure (= 400 copies/ml) in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).